<DOC>
	<DOCNO>NCT02208804</DOCNO>
	<brief_summary>The objective SIM trial investigate whether use Surefire Infusion System holmium-166 radioembolization increase posttreatment tumor non-tumor activity concentration ratio , compare use standard end-hole microcatheter .</brief_summary>
	<brief_title>Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization</brief_title>
	<detailed_description>Study design : clinical within-subject randomize controlled trial . Study population : 25 patient unresectable , chemorefractory , liver-dominant colorectal liver metastasis . Intervention : scout therapeutic dos holmium-166 microspheres administer leave right hepatic artery two sequential angiography procedure day . In subject , use Surefire Infusion System standard end-hole catheter randomly allocate infusion site ( left right hepatic artery ) . Baseline follow-up investigation : baseline follow-up , patient undergo physical examination laboratory investigation toxicity assessment , whole-body 18F-FDG-PET + dual-phase liver CT ( baseline 3-months follow-up ) tumor response assessment . After scout procedure therapeutic procedure , holmium-166 SPECT/CT obtain assessment microsphere distribution . Main study parameters/endpoints : The primary endpoint tumor non-tumor activity concentration ratio SPECT/CT . Secondary endpoint include mean absorbed dos radioactivity tumorous healthy liver tissue , tumor response , predictive value holmium-166 scout dose infusion efficiency . These endpoint compare Surefire Infusion System standard microcatheter infusion . A dose-response relationship , clinical toxicity overall survival assess entire cohort .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>Written inform consent Histopathologically confirm diagnosis adenocarcinoma colon rectum Hepatic metastases measurable morphological appearance ( ≥ 1 cm ) cross sectional imaging , locate right leave hepatic arterial perfusion territory Unresectable , liver dominant disease Progressive disease second line chemotherapy chemotherapeutical treatment option due severe side effect unwillingness patient undergo systemic chemotherapy Age ≥ 18 year Expected adequacy followup World health organization performance score &gt; 2 Inadequate bone marrow function ( hemoglobin &lt; 6.0 mmol/l , leukocyte count &lt; 3.0 x 109/l , platelet count &lt; 75x 109/l ) , inadequate liver function ( bilirubin &gt; 35 µmol/l , aspartate aminotransferase / alanine aminotransferase ( AST/ALT ) &gt; 5 x upper limit normal ( ULN ) ) inadequate renal function ( creatinine &gt; 1.5 x ULN ) Prior hemihepatectomy Compromised biliary system ( biliary stent hepaticojejunostomy ) Child Pugh score B7 worse Active hepatitis B C Main portal vein thrombosis CT ( previous portal vein embolization ) Severe celiac axis stenosis CT Unsuitable hepatic arterial anatomy CT Treatment systemic chemotherapy within 4 week prior radioembolization Previous participation study classify class III radiation safety committee Bleeding diathesis Pregnancy breast feed Life expectancy &lt; 3 month Patients declare incompetent Any condition prevents safe treatment radioembolization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Colorectal Cancer Liver Metastases</keyword>
</DOC>